Site Editor

David S. Ettinger, MD, FACP, FCCP


ASCO 2022: Eftilagimod Alpha Plus Pembrolizumab in NSCLC

By: Kayci Reyer
Posted: Monday, June 27, 2022

Findings from the extended first-line non–small cell lung cancer (NSCLC) cohort of the phase II TACTI-002 trial, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9003), showed that the combination of eftilagimod alpha plus the PD-L1 inhibitor pembrolizumab was safe and active in patients with NSCLC who were unselected for PD-L1. Enriqueta Felip, MD, PhD, of Vall d’Hebron Institute of Oncology, Barcelona, and colleagues noted that the LAG-3 protein may trigger more robust antitumor responses through the activation of T cells.

Between March 2019 and November 2021, the study enrolled 114 patients with metastatic NSCLC, 74% of whom were men. The Eastern Cooperative Oncology Group performance status was 0 in 37% of patients and 1 in 63% of patients. A total of 88% had stage IV disease at the time of enrollment; squamous (35%) and nonsquamous (62%) disease was represented, along with every PD-L1 subgroup.

At the time of data cutoff in January 2022, the overall response rate was 37.3% among all patients and 41.8% among evaluable patients (n = 75). The disease control rate was 73.3%. Among patients with squamous versus nonsquamous disease, the response rate was 33.3% versus 40.3%, respectively. Responses were achieved across all PD-L1 subgroups. A total of 86% of responses were confirmed, and the median duration of response was not yet reached.

Dyspnea (33%), asthenia (30%), decreased appetite (22%), cough (20%), and anemia (20%) were among the most commonly occurring adverse events with the combination therapy. Overall, 19 patients (17%) discontinued treatment because of adverse events.

Patients received 30 mg of subcutaneous eftilagimod alpha every 2 weeks for eight 3-week cycles, then every 3 weeks for up to 1 year plus 200 mg of intravenous pembrolizumab every 3 weeks for up to 2 years. The median number of administrations was six for pembrolizumab and seven for eftilagimod alpha.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.